............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
Aureon Laboratories to Collaborate with UCSF on Research
Study to Construct Predictive Models for GM-CSF Treatment
Response in Patients with Prostate Cancer
Yonkers, New York, October 15, 2007 / – Aureon Laboratories,
Inc. announced today a research collaboration with the
University of California, San Francisco (UCSF) to
retrospectively analyze a Phase I clinical trial that examined
the effects of neoadjuvant treatment with granulocyte macrophage
colony stimulating factor (GM-CSF) prior to radical
prostatectomy.
The goal of the study will be to use Aureon’s Systems Pathology
platform to identify histological, molecular, and clinical
phenotypes within patient samples both pre and post treatment in
order to construct models that assist in predicting therapeutic
response. Aureon’s approach includes morphometric image analysis
of histological specimens and cell-type specific, multiplexed
molecular biomarkers. This information is integrated with
clinical data using multivariate analysis and associated with
clinical endpoints of interest.
Vijay Aggarwal, PhD, CEO and President of Aureon Laboratories
said, "We are very excited about collaborating with UCSF on this
research project. Aureon is developing Prostate Px®,
a prognostic test to assist men who are recently diagnosed with
prostate cancer and need more accurate information prior to
treatment. Now, Aureon’s powerful technology platform will be
used, in a complementary way to assist research that may have
implications for prostate cancer vaccine development." Dr.
Aggarwal added, "Ultimately, Aureon’s primary goal is to provide
more information for men who are diagnosed with prostate
cancer."
About Aureon Laboratories
Aureon Laboratories' mission is to enable personalized patient
care through predictive pathology. Aureon has developed a high
throughput Systems Pathology technology platform to predict
individual clinical outcomes through the interrogation of tissue
and is the basis for the Prostate Px®
test which will provide physicians and patients with a unique
insight into the likelihood of prostate cancer recurrence and
progression at the time of biopsy and diagnosis. For more
information about Aureon or Prostate Px⊕, go to
www.aureon.com
or call 1-888-SYS-PATH.
Note
Prostate Px, Prostate Px® and Px
SCORE are registered trademarks of Aureon Laboratories, Inc.
Contact
Jason Alter, Ph.D.
Phone: 914-377-4036
Fax: 914-377-4001
Jason.Alter@Aureon.com
Source
Aureon Laboratories, Inc. |